Summary
Biogen Inc. announced a key addition to its Board of Directors, effective January 1, 2024. Monish Patolawala has been elected as a new director, filling a vacancy and serving until the 2024 Annual Meeting. Mr. Patolawala's expertise is particularly noteworthy as he qualifies as an "audit committee financial expert," a designation important for oversight of financial reporting and internal controls. This appointment suggests a continued focus on robust financial governance and potentially strengthens the composition of the Board's Audit Committee, should he be appointed to it.
Key Highlights
- 1Monish Patolawala appointed as a new Biogen Inc. director, effective January 1, 2024.
- 2Director appointment fills a vacancy and has a term expiring at the 2024 Annual Meeting.
- 3Mr. Patolawala is recognized as an "audit committee financial expert" per SEC regulations.
- 4The Board of Directors may appoint Mr. Patolawala to the Audit Committee.
- 5Mr. Patolawala will enter into a standard director indemnification agreement with Biogen.
Frequently Asked Questions
Monish Patolawala is a newly elected director to Biogen's Board, effective January 1, 2024. His appointment is significant because he is qualified as an "audit committee financial expert," indicating strong financial acumen and experience relevant to overseeing financial reporting and internal controls, which is a valuable asset for any public company's board.
An "audit committee financial expert" possesses a deep understanding of accounting principles and practices, financial statement preparation and disclosure, internal accounting controls, and audit committee functions. This expertise is crucial for effective oversight of a company's financial reporting process and audit.
The filing states that the Board of Directors 'may' appoint Mr. Patolawala to the Board's Audit Committee. While his qualification suggests he is a strong candidate, the final appointment to the committee will be determined by the Board.
Mr. Patolawala will enter into an indemnification agreement with Biogen on the same terms as other directors. This is a standard agreement that protects directors from personal liability for actions taken in their capacity as a director.